Coronary Artery Bypass Graft Market Report 2025

The coronary artery bypass graft market size has grown strongly in recent years. It will grow from $12.58 billion in 2024 to $13.66 billion in 2025 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to aging population, healthcare infrastructure growth, rising cardiovascular diseases, awareness campaigns, insurance coverage.

The coronary artery bypass graft market size is expected to see strong growth in the next few years. It will grow to $19.32 billion in 2029 at a compound annual growth rate (CAGR) of 9.1%. The growth in the forecast period can be attributed to ambulatory surgery centers (ASCS) growth, digital health integration, telemedicine growth, remote patient monitoring devices, patient-centric approaches. Major trends in the forecast period include advancements in surgical techniques, collaborative research, robotics in surgery, biodegradable implants, ai for diagnostic purposes, virtual reality training for surgeons.

The anticipated rise in the prevalence of cardiovascular diseases is poised to propel the expansion of the coronary artery bypass graft market in the future. Cardiovascular disease (CVD) encompasses various heart and blood vessel ailments. To reduce the risk of heart attacks, a coronary artery bypass graft (CABG) creates a new pathway for blood flow around blocked or partially blocked arteries in the heart. As per a journal published by Oxford University Press, a UK-based university press, the percentage of people affected by peripheral artery diseases is expected to increase by 50% by 2045. Consequently, the increased prevalence of cardiovascular diseases drives the growth of the coronary artery bypass graft market.

The growing geriatric population is anticipated to be a driving force behind the expansion of the coronary artery bypass graft market. The geriatric population consists of individuals who are elderly or of advanced age. Coronary artery bypass graft (CABG) surgery addresses severe coronary artery disease (CAD) in the geriatric population by bypassing blocked or narrowed arteries with healthy blood vessels. This restores blood flow to the heart muscle and improves its function. According to the World Health Organization, globally, one in six people will be 60 or older by 2030, and the number of individuals in this age group is expected to double to 2.1 billion by 2050. Additionally, a report by the UK Parliament's House of Commons Library indicates that by 2043, seniors will make up 24% of the total population in the UK, reaching 17.4 million people. Therefore, the increasing geriatric population is fostering the growth of the coronary artery bypass graft market.

Strategic collaboration emerges as a prominent trend gaining traction in the coronary artery bypass graft market, with major companies focusing on partnerships to fortify their positions and gain a competitive edge. For example, Medtronic plc, a US-based medical device company, collaborated with CathWorks, an Israel-based medical equipment manufacturer. The collaboration involves Medtronic investing a maximum of $75 million in CathWorks and jointly promoting CathWorks' FFRangio System in the United States, Japan, and Europe. Another instance is the collaboration between Etiometry, a US-based clinical decision-support software provider, and Terumo Cardiovascular, a US-based manufacturer of medical devices for cardiac and vascular surgery. This collaboration aims to provide advanced clinical decision support for adult cardiac surgery patients during and after their post-surgical recovery.

Major companies in the coronary artery bypass graft market are focusing on innovative advancements like surgical robotic systems to enhance precision and minimize invasiveness, thereby improving patient outcomes. They are also exploring AI and minimally invasive techniques to optimize procedures and reduce recovery times. A surgical robotic system is a high-tech platform that assists surgeons in conducting minimally invasive procedures with greater precision and visualization. It typically consists of robotic arms, advanced imaging, and a console for the surgeon to control the instruments. For example, in October 2023, SS Innovations International Inc., a US-based manufacturer of surgical and medical instruments, launched the SSi Mantra surgical robotic system. This system is designed to offer advanced, cost-effective robotic surgery solutions across various specialties, including cardiac procedures. Its key advantages include improved surgical precision, shorter recovery times through minimally invasive techniques, and the integration of machine learning to enhance safety and efficiency during operations.

In August 2022, Medtronic plc, a US-based medical device company, completed the acquisition of Affera Inc. for an undisclosed amount. This acquisition enhances Medtronic's cardiac ablation lineup by introducing a cardiac mapping and navigation platform, incorporating a distinctive diagnostic tool, focused pulsed field technology, and a radiofrequency ablation solution. Affera Inc. is a US-based medical technology company specializing in coronary artery bypass graft (CABG) procedures.

Major companies operating in the coronary artery bypass graft market include CryoLife Inc., Johnson & Johnson Co, Abbott Laboratories, Medtronic plc, Stryker Corporation, Northwell Health, Boston Scientific Corporation, Penn Medicine, Geisinger Health System Co, Terumo Corporation, Edwards Lifesciences Corporation, Main Line Health Inc., Getinge AB, Teleflex Incorporated, W. L. Gore & Associates Inc., Guidant Group, LivaNova PLC, AtriCure Inc., Peter Surgical, Cardiva Medical Inc., Genesee Biomedical Inc., Dextera Surgical Inc., Cardica Inc., Maquet Holding B.V. & Co.KG, Vitalitec International Medizintechnik GmbH, Hancock Jaffe Laboratories.

North America was the largest region in the coronary artery bypass graft market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the coronary artery bypass graft market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the coronary artery bypass graft market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

A coronary artery bypass graft (CABG) is a surgical intervention designed to treat coronary artery disease. This procedure is performed when the coronary arteries, responsible for delivering blood to the heart, become narrowed or blocked, potentially leading to angina or a heart attack.

The primary procedures for coronary artery bypass grafting include single coronary artery bypass graft (CABG) surgery, double coronary artery bypass graft (CABG) surgery, triple coronary artery bypass graft (CABG) surgery, quadruple coronary artery bypass graft (CABG) surgery, and others. Single coronary artery bypass graft (CABG) surgery is a surgical intervention utilized for the management of coronary heart disease. Both off-pump and on-pump methods are employed by various healthcare facilities, including hospitals, cardiology clinics, research institutes, and other end-users.

The coronary artery bypass graft research report is one of a series of new reports that provides coronary artery bypass graft market statistics, including the coronary artery bypass graft industry's global market size, regional shares, competitors with coronary artery bypass graft market share, detailed coronary artery bypass graft market segments, market trends and opportunities, and any further data you may need to thrive in the coronary artery bypass graft industry. This coronary artery bypass graft market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The coronary artery bypass graft market consists of revenues earned by entities by providing services such as bypass grafts, peripheral vascular grafts, hemodialysis access grafts, and endovascular stent grafts. The market value includes the value of related goods sold by the service provider or included within the service offering. The coronary artery bypass graft market also includes sales of forceps, vascular forceps, grasping forceps, needle holders, scissors, and clamps. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.